Medical and Physiological Benefits and Mechanisms of Reduced Sitting Without Meeting the Current Physical Activity Recommendations
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Metabolic Syndrome
- Sponsor
- Turku University Hospital
- Enrollment
- 64
- Locations
- 1
- Primary Endpoint
- The change in whole-body insulin sensitivity
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
The most important objective of this randomized controlled trial in subjects with increased cardiovascular and metabolic risk factors is to investigate whether only reduced daily sitting improves human cardiovascular and metabolic health during a six-month intervention. It is hypothesized and expected that only reduced sitting, without formal physical activity or exercise training, affects favorably cardiovascular and metabolic health.
Investigators
Ilkka Heinonen
Principal Investigator
University of Turku
Eligibility Criteria
Inclusion Criteria
- •Physically inactive (less than 120 minutes of moderate intensity exercise per week measured by the activity monitor during run-in)
- •Sitting time ≥ 10 h /day (measured by the activity monitor during run-in)
- •BMI 25-40
- •Blood pressure \< 160/100 mmHg
- •Fasting plasma glucose \< 7.0 mmol/l
- •Fulfills the criteria of the metabolic syndrome according to Alberti et al 2009
Exclusion Criteria
- •History of a cardiac event
- •Insulin or medically treated diabetes
- •Any chronic disease or condition that could create a hazard to the subject safety, endanger the study procedures or interfere with the interpretation of study results
- •Presence of ferromagnetic objects that would make MR imaging contraindicated
- •Abundant use of alcohol
- •Use of narcotics
- •Smoking of tobacco or consuming snuff tobacco
- •Diagnosed depressive or bipolar disorder
- •Previous PET imaging or considerable exposure to radiation
Outcomes
Primary Outcomes
The change in whole-body insulin sensitivity
Time Frame: The change from baseline to 6 months
M-value during the hyperinsulinemic euglycemic clamp
The change in skeletal muscle insulin-stimulated glucose uptake
Time Frame: The change from baseline to 6 months
Glucose uptake in the femoral muscles will be measured by positron emission tomography (PET) with \[18F\]-labelled fluoro-deoxy-glucose (FDG) tracer during hyperinsulinemic euglycemic clamp
Secondary Outcomes
- The change in maximal oxygen uptake(The change from baseline to 6 months)
- The change in plasma glucose(The change from baseline to 6 months)
- daily hours spent physically active(through study completion, an average of 6 months)
- The change in liver adiposity(The change from baseline to 6 months)
- The change in body fat percentage(The change from baseline to 6 months)
- The change in HbA1c(The change from baseline to 6 months)
- daily sitting hours(through study completion, an average of 6 months)